Sotera Health Co.

How big is Sotera Health Co.?

As of Jun 18, Sotera Health Co. has a market capitalization of $3.14 billion, with net sales of $1.11 billion and a net profit of $24.80 million for the latest four quarters. The balance sheet shows shareholder's funds of $404.91 million and total assets of $3.19 billion.

As of Jun 18, Sotera Health Co. has a market capitalization of 3,142.38 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,106.78 million and a net profit of 24.80 million for the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024.<BR><BR>As of December 2024, the balance sheet shows shareholder's funds of 404.91 million and total assets of 3,187.90 million.

What does Sotera Health Co. do?

Sotera Health Co. is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $255 million and a net profit of -$13 million. It has a market cap of $3.14 billion and key metrics include a P/E ratio of 36.00 and a debt-to-equity ratio of 4.64.

Overview:<BR>Sotera Health Co. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 255 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,142.38 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 36.00 <BR>Debt Equity: 4.64 <BR>Return on Equity: 23.53% <BR>Price to Book: 7.59 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Sotera Health Co.?

Is Sotera Health Co. overvalued or undervalued?

As of July 7, 2025, Sotera Health Co. is considered very expensive with a P/E ratio of 36 and has underperformed the S&P 500 by -4.6% over the past year, indicating significant overvaluation compared to its peers.

As of 7 July 2025, the valuation grade for Sotera Health Co. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 36, a Price to Book Value of 8.52, and an EV to EBITDA of 10.60. In comparison, peers such as Lantheus Holdings, Inc. have a much lower P/E ratio of 10.13, and Haemonetics Corp. shows a more attractive EV to EBITDA of 10.38, highlighting the disparity in valuation.<BR><BR>Recent stock performance shows that Sotera Health Co. has underperformed against the S&P 500 over the past year, with a return of -4.6% compared to the index's 17.14%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Sotera Health Co. is overvalued in the current market environment.

Is Sotera Health Co. technically bullish or bearish?

As of October 10, 2025, Sotera Health Co. shows a mildly bullish trend with positive MACD and Bollinger Bands, despite some caution from Dow Theory, having outperformed the S&P 500 year-to-date but lagged over the past year.

As of 10 October 2025, the technical trend for Sotera Health Co. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands are also showing a mildly bullish stance in both weekly and monthly time frames. However, the Dow Theory indicates a mildly bearish trend on the weekly chart, which adds some caution. <BR><BR>In terms of returns, Sotera Health has outperformed the S&P 500 year-to-date with a return of 14.55% compared to 11.41%, but it has lagged over the past year with a return of 2.28% versus 13.36% for the index. Overall, the current technical stance is mildly bullish, driven by positive MACD and Bollinger Bands, despite some bearish signals from the Dow Theory and OBV.